cefepime Powder for solution for injection 1 g, 2 g

Dossier type
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
Unavailable markets
Algeria , Angola , Bahrain , Bulgaria , Cameroon , Colombia , Egypt , Ghana , Iran , Iraq , Israel , Jordan , Kuwait , Lebanon , Libya , Lithuania , Morocco , Nigeria , Oman , Qatar , Saudi Arabia , Senegal , South Africa , Sudan , Syria , Tunisia , United Arab Emirates , Vietnam , Yemen
Manufacturer #686
A pharmaceutical manufacturer based in the EU that has been active in 100+ countries selling its products in Europe, CIS, North America, LATAM, Africa, and Asia for 30+ years. The key production line is Rx. Main therapeutic areas include antibiotics, neurology, and cardiovascular. The main dosage form is injectable. The company's production lines are GMP-compliant. The company possesses different production lines in the EU.

Manufacturer usually replies in 5 days

Cefepime is an antibiotic used to treat a wide range of bacterial infections, including intraabdominal, kidney, skin, urinary tract infections as well as pneumonia. Suppliers of cefepime market it in the form of powders for injectable solutions. The developer and earliest manufacturer of cefepime is Bristol-Myers Squibb who first introduced it into the market in 1994 under the trade name Maxipime. Currently, major manufacturers of cefepime medications include companies such as Berr Chem, Hangzhou Viwa, Nectar Lifesciences, ACS Dobfar, and Qilu Pharmaceutical. Cefepime suppliers and distributors market both generic and trade name formulations of the drug. Buyers are advised that online sellers may attempt to market fraudulent versions of the drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified cefepime manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. The retail prices per 10g of cefepime powder falls into an approximate range of 120 EUR to 160 EUR.